Does Rallies show 13F holders for BBIO?

Yes. Rallies tracks hedge fund and 13F ownership data for BBIO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.

BBIO (BridgeBio Pharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, BBIO trades at $67.69 with a market cap of $12.79B and a P/E ratio of -18.26. BBIO moved +3.41% today. Year to date, BBIO is -7.08%; over the trailing twelve months it is +102.37%. Its 52-week range spans $21.72 to $84.94. Analyst consensus is strong buy with an average price target of $109.00. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BBIO stock?

Hedge funds tracked by Rallies that own BBIO include Viking Global, Farallon Capital, Panagora Asset, Duquesne Family, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BridgeBio Pharma, Inc. Common Stock.

BBIO Key Metrics

Key financial metrics for BBIO
Metric	Value
Price	$67.69
Market Cap	$12.79B
P/E Ratio	-18.26
EPS	$-3.73
Dividend Yield	0.00%
52-Week High	$84.94
52-Week Low	$21.72
Volume	2.32M
Avg Volume	0
Revenue (TTM)	$579.96M
Net Income	$-729.88M
Gross Margin	95.13%

Top Hedge Funds Holding BBIO

Viking Global holds 11.84M shares of BBIO, changed -17.73% as of Mar 31, 2026.
Farallon Capital holds 9.37M shares of BBIO, changed +4.08% as of Mar 31, 2026.
Panagora Asset holds 742.12K shares of BBIO, changed +0.44% as of Mar 31, 2026.
Duquesne Family holds 438.05K shares of BBIO, changed +0.00% as of Mar 31, 2025.
Bridgewater Associates holds 259.46K shares of BBIO, changed +500.99% as of Mar 31, 2026.

Latest BBIO News

BridgeBio Pharma Acoramidis Reduces All-Cause Death 44.7% and Cardiovascular Death 49.3% at 54 Months — May 12, 2026
BridgeBio Files Encaleret NDA After 76% Phase 3 Success, Targets Early 2027 Launch — May 12, 2026
BridgeBio’s Acoramidis Cuts sTTR Variability to 9.5% and Reduces Hospitalizations 34% — May 11, 2026
BridgeBio Pharma Posts $195M Q1 Revenue, Bernstein Raises Target to $114 — May 8, 2026
BridgeBio Q1 Revenues $194.5M, Initiates $500M Buyback and BBP-418 NDA — May 7, 2026

Recent BBIO Insider Trades

Scott Randal W. sold 6.20K (~$413.46K) on May 15, 2026.
Scott Randal W. sold 2.09K (~$141.00K) on May 15, 2026.
Scott Randal W. sold 1.51K (~$103.16K) on May 15, 2026.

BBIO Analyst Consensus

17 analysts cover BBIO: 0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.00.

Common questions about BBIO

Who owns BBIO stock?: Hedge funds tracked by Rallies that own BBIO include Viking Global, Farallon Capital, Panagora Asset, Duquesne Family, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BridgeBio Pharma, Inc. Common Stock.
Does Rallies show 13F holders for BBIO?: Yes. Rallies tracks hedge fund and 13F ownership data for BBIO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BBIO. It does not provide personalized investment advice.